A Prescription Drug User Fee Act (PDUFA) target action date for apitegromab has been set for Sept. 22, 2025.

Data from the SAPPHIRE study formed the basis of Scholar Rock's U.S. Food and Drug Administration request to approve ...

After bringing Zolgensma to market in 2019 as the first gene therapy for spinal muscular atrophy, Novartis is back with an intrathecal formulation intended for older patients.

Seattle City Council President Sara Nelson joined SMN live in the studio to discuss the new bill approved by the council to ...

Scholar Rock will present new Phase 3 SAPPHIRE trial data on apitegromab at the 2025 MDA conference, highlighting efficacy ...

CRANBROOK, BC / ACCESS Newswire / March 17, 2025 / Eagle Plains Resources Ltd. (TSX-V:EPL) ("EPL" or "Eagle Plains") and Sun ...

A child with a rare genetic disorder — spinal muscular atrophy type I — was treated prenatally for the first time. Courtesy of Jakob Owens  via Unsplash During an amniocentesis test, a long, thin ...

Scholar Rock (SRRK) announced that new efficacy and safety data from the Phase 3 pivotal SAPPHIRE trial will be presented in multiple clinical ...

A multidisciplinary approach, early diagnosis, and comprehensive caregiver education are crucial in effectively managing ...

The spring months (March-May) are typically the hottest in Mexico City, with temperatures cooling off once the rainy season ...

Graeme Shinnie marked his 600th first-team game with a goal and has now set himself a landmark of at least another 100 games. The Aberdeen captain made his milestone appearance in the 4-1 Scottish ...